普伐他汀对杂合子家族性高胆固醇血症患者脂质转运蛋白和卵磷脂胆固醇酰基转移酶的影响。

Effects of pravastatin on lipid transfer protein and lecithin cholesterol acyltransferase in heterozygous familial hypercholesterolemia.

作者信息

Fusegawa Y, Tada H, Oguma T, Shiina Y, Moriguchi E H, Tanabe T, Tamachi H, Tomoda H, Goto Y

机构信息

First Department of Internal Medicine, Tokai University School of Medicine, Japan.

出版信息

Tokai J Exp Clin Med. 1993 Dec;18(3-6):81-6.

PMID:7701533

Abstract

The effects of HMG CoA reductase inhibitor PRAVASTATIN on plasma lipoprotein levels, lipid transfer protein (LTP) activity and lecithin cholesterol acyltransferase (LCAT) activity were investigated in 20 patients with heterozygous familial hypercholesterolemia. Plasma total cholesterol decreased from 299.2 +/- 45.2 to 245.9 +/- 45.1 (mean +/- SD in mg/dl) (p < 0.0001), low density lipoprotein (LDL) cholesterol from 221.1 +/- 47.6 to 164.9 +/- 48.1 (p < 0.0001) and LDL-triglycerides from 38.0 +/- 10.2 to 30.2 +/- 8.8 (p < 0.0001). High density lipoprotein (HDL) cholesterol increased from 60.1 +/- 13.9 to 63.1 +/- 17.0 (p = 0.0264). The HDL-cholesterol: HDL-triglycerides ratio increased from 3.91 +/- 1.14 to 4.91 +/- 1.65 (p = 0.0029). Lipid transfer protein (LTP) activity (as % of transferred cholesteryl ester (CE)) decreased from 4.68 +/- 2.47 to 3.70 +/- 2.31 (p = 0.0024) and LCAT activity decreased from 113.1 +/- 29.9 (U/L) to 97.0 +/- 22.7. There was a negative correlation between LTP/LCAT ratio and HDL-C levels. These results suggested that the changes in plasma HDL-cholesterol concentrations during treatment with pravastatin may be related to the decreases in LTP and LCAT activity due to this drug.

摘要

在20例杂合子家族性高胆固醇血症患者中，研究了HMG CoA还原酶抑制剂普伐他汀对血浆脂蛋白水平、脂质转运蛋白（LTP）活性和卵磷脂胆固醇酰基转移酶（LCAT）活性的影响。血浆总胆固醇从299.2±45.2降至245.9±45.1（mg/dl，均值±标准差）（p<0.0001），低密度脂蛋白（LDL）胆固醇从221.1±47.6降至164.9±48.1（p<0.0001），LDL-甘油三酯从38.0±10.2降至30.2±8.8（p<0.0001）。高密度脂蛋白（HDL）胆固醇从60.1±13.9升至63.1±17.0（p = 0.0264）。HDL-胆固醇：HDL-甘油三酯比值从3.91±1.14升至4.91±1.65（p = 0.0029）。脂质转运蛋白（LTP）活性（以转移的胆固醇酯（CE）的百分比表示）从4.68±2.47降至3.70±2.31（p = 0.0024），LCAT活性从113.1±29.9（U/L）降至97.0±22.7。LTP/LCAT比值与HDL-C水平之间存在负相关。这些结果表明，普伐他汀治疗期间血浆HDL-胆固醇浓度的变化可能与该药物导致的LTP和LCAT活性降低有关。